Acute effects of zolpidem extended-release on cognitive performance and sleep in healthy males after repeated nightly use.
- 1 February 2012
- journal article
- research article
- Published by American Psychological Association (APA) in Experimental and Clinical Psychopharmacology
- Vol. 20 (1) , 28-39
Abstract
The extended-release formulation of zolpidem (Ambien CR) is approved for the treatment of insomnia without a treatment duration limit. Acutely zolpidem impairs performance, and no research to date has examined whether tolerance develops to these performance impairments during nighttime awakening. The present double-blind, placebo-controlled study examined whether tolerance develops to zolpidem-induced acute performance impairment after repeated (22-30 days) nightly use. Effects of bedtime administration of zolpidem extended-release (ZOL; 12.5 mg) were tested on a battery of performance measures assessed during a forced nighttime awakening in 15 healthy male volunteers who completed overnight polysomnographic recording sessions in our laboratory at baseline and after approximately a month of at-home ZOL. As expected, bedtime ZOL administration was associated with changes in sleep architecture and impairments across all performance domains during nighttime testing (psychomotor function, attention, working memory, episodic memory, metacognition) with no residual next morning impairment. Tolerance did not develop to the observed ZOL-related impairments on any outcome. Possible evidence of acute abstinence effects after discontinuation of ZOL was observed on some performance and sleep outcomes. Overall, these findings suggest that performance is significantly impaired during nighttime awakening even after a month of nightly ZOL administration, and these impairments could significantly impact safety should nighttime awakening require unimpaired functioning (e.g., driving; combat-related activities in the military).Keywords
Funding Information
- National Institute on Drug Abuse (DA-11936; DA-07209)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (AR-054871)
- National Institutes of Health (M01RR-02719)
This publication has 48 references indexed in Scilit:
- Modafinil and Zolpidem Use by Emergency Medicine ResidentsAcademic Emergency Medicine, 2009
- Road traffic accident risk related to prescriptions of the hypnotics zopiclone, zolpidem, flunitrazepam and nitrazepamSleep Medicine, 2008
- Effects of prolonged‐release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteersHuman Psychopharmacology: Clinical and Experimental, 2008
- Practice Parameters for the Indications for Polysomnography and Related Procedures: An Update for 2005SLEEP, 2005
- Fatigue and use of go/no-go pills in extraordinarily long combat sorties.2004
- Residual Effects of Middle-of-the-Night Administration of Zaleplon and Zolpidem on Driving Ability, Memory Functions, and Psychomotor PerformanceJournal of Clinical Psychopharmacology, 2002
- Residual effects of zaleplon and zolpidem following middle of the night administration five hours to one hour before awakeningHuman Psychopharmacology: Clinical and Experimental, 2001
- A comparison of the residual effects of zaleplon and zolpidem following administration 5 to 2 h before awakeningBritish Journal of Clinical Pharmacology, 1999
- Triazolam and zolpidem: effects on human memory and attentional processesPsychopharmacology, 1999
- Short-term safety profile of zolpidem: objective measures of cognitive effectsEuropean Psychiatry, 1997